Gain Therapeutics grants 25,000 options to director

Gain Therapeutics, Inc. granted director GOLDSTEIN DOV A MD a stock option covering 25,000 shares of common stock at an exercise price of $1.68 per share.

Rhea-AI Filing Summary

Gain Therapeutics, Inc. granted director GOLDSTEIN DOV A MD a stock option covering 25,000 shares of common stock at an exercise price of $1.68 per share. The option vests in 12 equal monthly installments beginning July 24, 2026, subject to his continuous service, and expires on July 15, 2036. Following this grant, he holds options on 25,000 shares.

Insider Trade Summary

Grant/Award: 25,000 shares

Grant/Award 1 txn

Insider GOLDSTEIN DOV A MD

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	25,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 25,000 contracts (Direct)

Footnotes (1)

1. F1. The option vests in 12 equal monthly installments commencing on July 24, 2026, subject to the Reporting Person's continuous service through the applicable vesting date.

Key Figures

Stock options granted: 25,000 shares Exercise price: $1.68 per share Options held after grant: 25,000 shares +2 more

5 metrics

Stock options granted 25,000 shares Director stock option grant on July 15, 2026

Exercise price $1.68 per share Conversion or exercise price of the granted option

Options held after grant 25,000 shares Total options following the reported transaction

Vesting schedule 12 monthly installments Equal monthly vesting beginning July 24, 2026

Option expiration July 15, 2036 Expiration date of the granted stock option

Key Terms

Stock Option (right to buy), exercise price, vests in 12 equal monthly installments, expiration date

4 terms

Stock Option (right to buy) financial

"Security title noted as Stock Option (right to buy)."

exercise price financial

"Conversion or exercise price reported as $1.6800 per share."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests in 12 equal monthly installments financial

"The option vests in 12 equal monthly installments commencing on July 24, 2026."

expiration date financial

"Option expiration date reported as 2036-07-15."

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock option grant did Gain Therapeutics (GANX) give to director Goldstein?

Gain Therapeutics granted director GOLDSTEIN DOV A MD a stock option for 25,000 shares of common stock at an exercise price of $1.68 per share. The grant represents his reported holdings of options on 25,000 shares after the transaction.

What is the exercise price of the new Gain Therapeutics (GANX) stock option?

The granted stock option has an exercise price of $1.68 per share. This allows the director to purchase up to 25,000 shares of Gain Therapeutics common stock at $1.68, regardless of the market price when the option is exercised before expiration.

How do the Gain Therapeutics (GANX) options granted to Goldstein vest?

The option vests in 12 equal monthly installments starting on July 24, 2026. Each month, one-twelfth of the 25,000-share grant becomes exercisable, provided the director continues in service through each applicable vesting date.

When do the newly granted Gain Therapeutics (GANX) stock options expire?

The stock option granted to the director expires on July 15, 2036. After this expiration date, any unexercised portion of the 25,000-share option will no longer be exercisable, even if it had previously vested under the vesting schedule.

How many Gain Therapeutics (GANX) option shares does Goldstein hold after this grant?

Following the grant, the director is reported to hold options on 25,000 shares of Gain Therapeutics common stock. This total corresponds to the full size of the new option award reported in the transaction details.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/17/2026 - 08:33 AM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GOLDSTEIN DOV A MD

(Last) (First) (Middle)

C/O GAIN THERAPEUTICS, INC.

4800 MONTGOMERY LANE, SUITE 220

(Street)

BETHESDA MARYLAND 20814

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Gain Therapeutics, Inc. [ GANX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.68	07/15/2026		A		25,000		(1)	07/15/2036	Common Stock	25,000	$0.00	25,000	D

Explanation of Responses:

1. The option vests in 12 equal monthly installments commencing on July 24, 2026, subject to the Reporting Person's continuous service through the applicable vesting date.

	/s/ Dov A. Goldstein	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)